search
Back to results

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

Primary Purpose

Uncontrolled Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 3
Locations
India
Study Type
Interventional
Intervention
CPL-2009-0031 140 mg
Sitagliptin 100mg
Sponsored by
Cadila Pharnmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uncontrolled Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male and female adult patient of 18-65 years with uncontrolled type 2 diabetes Mellitus (T2DM).
  • Patients with HbA1c ≥ 7 to 10 and those on oral hypoglycemic agents ≤ 2 other than Insulin and Gliptins.
  • BMI in the range of 18.5 - 35 kg/m2.
  • All patients must be willing to give informed consent and can understand & complying protocol requirement.
  • Patients who are in good health at the time of entry into the study as determined by medical, medication and hypersensitivity histories, clinical examination, vital sign measurements, chest X-ray, 12-lead ECG measurement and clinical judgment of the investigator.
  • Documented negative test for human immuno virus (HIV), Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV).

Exclusion Criteria:

  • Those who are on insulin and not ready for wash out of 3 months.
  • Those who are on gliptin and not ready for wash out of 3 months.
  • Those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes.
  • Those scheduled for or who had undergone surgery.
  • Those with a severe infection or serious injury
  • Pregnant and lactating women.
  • Hypersensitivity and contraindication to DPP-IV inhibitors or excipients of investigational drug formulation.
  • Hypertensive patients with blood pressure ≥160/100 mm of Hg.
  • History of ischemic heart disease (as evident from ECG), stroke and/or transient ischemic attack.
  • Debilitating neurological or psychiatric disorders
  • History or currently consuming abusing drugs or alcohol.
  • Serious hepatic or renal impairment (liver dysfunction as evidenced by SGPT/SGOT level of 2.5 X ULN and renal dysfunction as evidenced by creatinine level 2.5 X ULN).
  • Patient with abnormal clinical chemistry, hematology or urinalysis results that are considered clinically significant by the investigator or the sponsor.
  • Patient has any concurrent illness which, in the opinion of the investigator or coinvestigator, may interfere with treatment or evaluation of safety or completion of this study.
  • In the investigator's judgment, the patient is unable to adhere to the treatment regimen, protocol procedures or study requirements.
  • Participation in another clinical trial in the past 3 months.
  • Patients with history of smoking or currently having smoking habit will not be included in the study.

Sites / Locations

  • A C Subba Reddy Government Medical College and Hospital
  • Downtown Hospital
  • SSG Hospital
  • Bangalore Diabetes Centre
  • Dhadiwal Hospital
  • Ashirwad Hospital & Research Centre
  • S.P. Medical College and A.G. Hospital
  • Bhandari Clinic & Research Centre
  • Sanjivini Lung Centre
  • Nilratan Sircar Medical College & Hospital
  • Life Line Diagnostic Centre cum Nursing Home
  • Apollo Hospital International Ltd

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

CPL-2009-0031 140 mg

Sitagliptin 100 mg

Arm Description

Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks

Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks

Outcomes

Primary Outcome Measures

Change in HbA1c level
To evaluate HbA1c levels between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg

Secondary Outcome Measures

Fasting Blood Sugar (FBS) level
To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg
Postprandial Blood Sugar (PPBS) level
To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg
Frequency of Serious Adverse Events
Determination of safety and tolerability of CPL-2009-0031 140 mg versus Sitagliptin 100 mg based on Frequency of serious adverse events
Number of hypoglycemic events
Determine number and severity of hypoglycemic events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg
Frequency of adverse events
Determine frequency and severity of adverse events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg

Full Information

First Posted
March 11, 2021
Last Updated
August 14, 2021
Sponsor
Cadila Pharnmaceuticals
Collaborators
New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India
search

1. Study Identification

Unique Protocol Identification Number
NCT04801199
Brief Title
Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus
Official Title
Prospective, Randomized, Double Blind, Parallel Group, Two Arm, Comparative, Multicenter, Clinical Study to Compare Efficacy and Safety of Oral CPL-2009-0031 140 mg of Cadila Pharmaceutical Limited, India Against Innovator Sitagliptin 100 mg in Patients With Uncontrolled Type-2 Diabetes Mellitus (T2DM)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2021
Overall Recruitment Status
Completed
Study Start Date
January 26, 2020 (Actual)
Primary Completion Date
January 13, 2021 (Actual)
Study Completion Date
February 11, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Cadila Pharnmaceuticals
Collaborators
New Millennium Indian Technology Leadership Initiative (NMITLI) program of Council of Scientific and Industrial Research, India

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This trial is a Phase-III, Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled clinical trial to determine the efficacy, safety, and tolerability of oral CPL-2009-0031 140 mg in comparison with Sitagliptin 100 mg in patients with Uncontrolled Type-2 Diabetes Mellitus (T2DM).
Detailed Description
In this phase-III trial, after due consent and completing initial 2-weeks of placebo run-in period with diet, exercise and counseling, eligible patients with uncontrolled T2DM will be randomized in balance to receive either once daily oral CPL-2009-0031 140 mg or Sitagliptin 100 mg. After completing 12 weeks of study post-randomization for regulatory submission, patients will be instructed for continuation of extension phase of treatment and follow up upto 36 weeks. HbA1c will be measured at screening, baseline, 12 weeks, 24 weeks and 36 weeks of treatment. While, Fasting Blood Sugar (FBS) and Postprandial Blood Sugar (PPBS) measurement will be performed every 2 weeks. The enrolled patients will be monitored for safety (AE and SAE) throughout the study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uncontrolled Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Prospective, Randomized, Double Blind, Parallel Group, Two arm, Comparative, Multicenter, controlled study
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Investigator, patient, study staff, data monitors and database personnel will be blinded to the study treatment.
Allocation
Randomized
Enrollment
355 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CPL-2009-0031 140 mg
Arm Type
Experimental
Arm Description
Single dose, Oral tablet containing 140 mg of CPL-2009-0031, Once daily for 36-weeks
Arm Title
Sitagliptin 100 mg
Arm Type
Active Comparator
Arm Description
Single dose, Oral tablet containing 100 mg of Sitagliptin, Once daily for 36-weeks
Intervention Type
Drug
Intervention Name(s)
CPL-2009-0031 140 mg
Intervention Description
Patients will receive OD CPL-2009-0031 140 mg for 36 weeks with or without breakfast with a glass of water.
Intervention Type
Drug
Intervention Name(s)
Sitagliptin 100mg
Intervention Description
Patients will receive OD Sitagliptin 100 mg for 36 weeks with or without breakfast with a glass of water.
Primary Outcome Measure Information:
Title
Change in HbA1c level
Description
To evaluate HbA1c levels between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg
Time Frame
Baseline, 12 weeks, 24 weeks and 36 weeks from onset of therapy
Secondary Outcome Measure Information:
Title
Fasting Blood Sugar (FBS) level
Description
To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg
Time Frame
Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy
Title
Postprandial Blood Sugar (PPBS) level
Description
To compare Fasting Blood Sugar between oral CPL-2009-0031 140 mg and oral Sitagliptin 100 mg
Time Frame
Every 2 week till 12 weeks and every 4 weeks between 12 weeks to 36 weeks from onset of therapy
Title
Frequency of Serious Adverse Events
Description
Determination of safety and tolerability of CPL-2009-0031 140 mg versus Sitagliptin 100 mg based on Frequency of serious adverse events
Time Frame
From randomization to end of 12 week, 24 week and 36-weeks therapy
Title
Number of hypoglycemic events
Description
Determine number and severity of hypoglycemic events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg
Time Frame
From randomization to end of 12 week, 24 week and 36-weeks therapy
Title
Frequency of adverse events
Description
Determine frequency and severity of adverse events of CPL-2009-0031 140 mg versus Sitagliptin 100 mg
Time Frame
From randomization to end of 12 week, 24 week and 36-weeks therapy

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female adult patient of 18-65 years with uncontrolled type 2 diabetes Mellitus (T2DM). Patients with HbA1c ≥ 7 to 10 and those on oral hypoglycemic agents ≤ 2 other than Insulin and Gliptins. BMI in the range of 18.5 - 35 kg/m2. All patients must be willing to give informed consent and can understand & complying protocol requirement. Patients who are in good health at the time of entry into the study as determined by medical, medication and hypersensitivity histories, clinical examination, vital sign measurements, chest X-ray, 12-lead ECG measurement and clinical judgment of the investigator. Documented negative test for human immuno virus (HIV), Hepatitis B surface antigen (HBsAg) and Hepatitis C virus (HCV). Exclusion Criteria: Those who are on insulin and not ready for wash out of 3 months. Those who are on gliptin and not ready for wash out of 3 months. Those with a history of severe ketosis, diabetic coma or pre-coma, or type 1 diabetes. Those scheduled for or who had undergone surgery. Those with a severe infection or serious injury Pregnant and lactating women. Hypersensitivity and contraindication to DPP-IV inhibitors or excipients of investigational drug formulation. Hypertensive patients with blood pressure ≥160/100 mm of Hg. History of ischemic heart disease (as evident from ECG), stroke and/or transient ischemic attack. Debilitating neurological or psychiatric disorders History or currently consuming abusing drugs or alcohol. Serious hepatic or renal impairment (liver dysfunction as evidenced by SGPT/SGOT level of 2.5 X ULN and renal dysfunction as evidenced by creatinine level 2.5 X ULN). Patient with abnormal clinical chemistry, hematology or urinalysis results that are considered clinically significant by the investigator or the sponsor. Patient has any concurrent illness which, in the opinion of the investigator or coinvestigator, may interfere with treatment or evaluation of safety or completion of this study. In the investigator's judgment, the patient is unable to adhere to the treatment regimen, protocol procedures or study requirements. Participation in another clinical trial in the past 3 months. Patients with history of smoking or currently having smoking habit will not be included in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anil Avhad, MBBS
Organizational Affiliation
Cadila Pharmaceutical Limited
Official's Role
Study Director
Facility Information:
Facility Name
A C Subba Reddy Government Medical College and Hospital
City
Nellore
State/Province
Andhra Pradesh
ZIP/Postal Code
524004
Country
India
Facility Name
Downtown Hospital
City
Guwahati
State/Province
Assam
ZIP/Postal Code
781006
Country
India
Facility Name
SSG Hospital
City
Vadodara
State/Province
Gujarat
ZIP/Postal Code
390001
Country
India
Facility Name
Bangalore Diabetes Centre
City
Bangalore
State/Province
Karnataka
ZIP/Postal Code
560043
Country
India
Facility Name
Dhadiwal Hospital
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
422002
Country
India
Facility Name
Ashirwad Hospital & Research Centre
City
Ulhasnagar
State/Province
Maharashtra
ZIP/Postal Code
421004
Country
India
Facility Name
S.P. Medical College and A.G. Hospital
City
Bīkaner
State/Province
Rajasthan
ZIP/Postal Code
334001
Country
India
Facility Name
Bhandari Clinic & Research Centre
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302015
Country
India
Facility Name
Sanjivini Lung Centre
City
Lucknow
State/Province
Uttar Pradesh
ZIP/Postal Code
226010,
Country
India
Facility Name
Nilratan Sircar Medical College & Hospital
City
Kolkata
State/Province
West Bengal
ZIP/Postal Code
700014
Country
India
Facility Name
Life Line Diagnostic Centre cum Nursing Home
City
Kolkata
State/Province
West Bengal
ZIP/Postal Code
70001
Country
India
Facility Name
Apollo Hospital International Ltd
City
Gandhinagar
ZIP/Postal Code
382428
Country
India

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=32963&EncHid=&modid=&compid=%27,%2732963det%27
Description
Clinical trial database uploaded on Clinical Trial Registry of India (CTRI)

Learn more about this trial

Effect of CPL-2009-0031 in the Treatment of Patients With Uncontrolled Type 2 Diabetes Mellitus

We'll reach out to this number within 24 hrs